Filing Flows › Zomedica (ZOMDF) › Q2 2026 › vs Q1 2026
Zomedica (ZOMDF) Q2 2026 vs Q1 2026 (quarter over quarter)
Zomedica's revenue rose $713K (+8%) from $8.8M in Q1 2026 to $9.5M in Q2 2026. The biggest changes: Consumables +$1.2M (+22%); Engineering −$265K (-21%); Capital −$135K (-7%).
Zomedica, Q2 2026: revenue $9.5M (+37% year over year), operating margin -42.9%, net loss $3.8M, operating cash flow −$2.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Consumables | $6.6M | $5.5M | $1.2M | +22% |
| Capital | $1.8M | $2.0M | −$135K | -7% |
| Engineering | $979K | $1.2M | −$265K | -21% |
| Other | $45K | $111K | −$66K | -59% |
| Revenue | $9.5M | $8.8M | $713K | +8% |
| Other income, net | $344K | $405K | −$61K | -15% |
| Net loss | $3.8M | $4.5M | −$769K | -17% |
| Costs & expenses | $13.6M | $13.7M | −$117K | -0.9% |
| Operating costs | $13.6M | $13.7M | −$104K | -0.8% |
| Income tax | $26K | $39K | −$13K | -33% |
| Cost of revenue | $3.5M | $3.3M | $156K | +5% |
| Research & development | $1.1M | $1.2M | −$84K | -7% |
| Sales & marketing | $3.7M | $3.8M | −$142K | -4% |
| General & admin | $5.4M | $5.4M | −$34K | -0.6% |
| Operating cash sources | $4.5M | $7.8M | −$3.3M | -43% |
| Depreciation & amortization | $1.8M | $1.9M | −$48K | -3% |
| Share-based compensation | $69K | $643K | −$574K | -89% |
| Cash used in operations | $2.6M | $5.3M | −$2.7M | -51% |
| Net loss absorbed | $3.8M | $4.5M | −$769K | -17% |
| Working capital & other | $698K | $3.3M | −$2.6M | -79% |
Questions
How much did Zomedica's revenue grow quarter over quarter in Q2 2026?
Zomedica's revenue rose $713K (+8%) from $8.8M in Q1 2026 to $9.5M in Q2 2026.
What drove Zomedica's revenue change in Q2 2026?
Consumables +$1.2M (+22%); Engineering −$265K (-21%); Capital −$135K (-7%).